Taiho Pharmaceutical Launches $50M Strategic Corporate Venture Capital Arm

Taiho Pharmaceutical Co., Ltd., a Tokyo, Japan-based oncology pharmaceutical company, has established a strategic corporate venture capital arm.

Led by President Sakae Asanuma, Taiho Ventures will be investing globally in startup companies discovering and developing innovative therapeutic products and/or drug-enabling platform technologies that demonstrate a clear potential to benefit cancer patients.

Taiho Ventures, a wholly owned subsidiary of Taiho Oncology, will initially make investments from the pooled amount of US$50m in companies operating in U.S., Europe and Japan.
The firm is based in California, USA.



Join the discussion